Research by the @mklevings lab team reveals a new dimension of CAR-#Treg biology, and has important implications for the design of CARs for clinical use in Tregs. #allograft
Learn more in @JCI_insight:
📗 https://t.co/KHI9jDbuVm
In this study in the current issue of @TransplantJrnl, @mklevings et al. describe a novel mouse model for studying human islet rejection while avoiding xenograft-versus-host disease. #VisualAbstract#TransplantTwitter https://t.co/a41XR5u7Ul
We are ✨hiring✨ not one, not two, but three new faculty positions in @SBME_UBC! The focuses are on cell therapies for autoimmune diseases, neuroengineering and immunoengineering. Passion for pranking @PZandstra on April Fool's desired, but not required. Please RT (RX? Idk)!
Beautiful work by @mklevings@briantfife showing how potent antigen-specific #Tregs can be in cellular biotherapy of #autoimmunity !👉Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes in mice. https://t.co/nRkiWoWAAR
We are looking to hire a research coordinator to join my lab at UBC and the team at IBD Centre of BC. The position will involve supporting our team to undertake research focusing on optimising medical and dietary therapies for IBD patients. Please retweet!
https://t.co/0v7mLZ3sEp
📢JOB ALERT 🥁
@UBCMicroImmuno is looking for FACULTY POSITIONS IN ANTIMICROBIAL RESISTANCE
The positions will start no earlier than July 1, 2023
#microbiology#immunology#Vancouver#Canada
▶️ Apply now details below 👇🏽
https://t.co/lHZqmVlf8x
Check out our GVHD protocol: "Modelling Graft-Versus-Host Disease in Mice Using Human Peripheral Blood Mononuclear Cells" @bioprotocolbyte from @mklevings lab. @dom_boardman1 @katienmac@mojibian
Dr. @Dom_Boardman1 and a team in Dr. Megan Levings' (@mklevings) lab developed the first chimeric antigen receptor (CAR) to target a microbial antigen! ���
They aim to develop an optimized #Treg #CellTherapy to treat inflammatory and autoimmune diseases.
https://t.co/JdUj0W0wwj
We’re #hiring a Clinical Trial Manager! This position will manage the ongoing UST1D2 clinical trial. The incumbent will be involved in a full range of research activities and will report to the Principal Investigator, Dr. Jan Dutz. More: https://t.co/1JaXf1XNn4
This study assessed the safety of ustekinumab, a #MonoclonalAntibody used in #psoriasis, in a small cohort of young #type1diabetes patients
Here, the researchers report on safety & immune-mechanistic data 👉https://t.co/QSeuTmkgqK
This review discusses the potential for immunoregulatory macrophages, innate lymphoid cells and regulatory T cells to promote beta cell regeneration in #type1diabetes@mklevings, @BruceVerchere, @sarah_crome, @MahdisMonajemi, @Colpitts_sarah, @mbudd177 https://t.co/j25uyhysTc
Dear Twitterverse, we have an opportunity to join the lab! See 👇 and consider being part of the many cool, well-funded projects we have going on! @TGHRI_UHN @UHN_Research @UofT @UofTVascular @PMunkCardiacCtr https://t.co/wLgothmThf
UBC Microbiology and Immunology is hiring! Tier I Canada Research Chair in Infectious Disease and Immunity. I love being part of this Department - come join us! @UBCMicroImmuno
https://t.co/rkVI9sn6VR
Protection of the endothelial glycocalyx in vascular allografts via the enzymatic ligation of immunosuppressive glycopolymers prevents allograft rejection after transplantation in the absence of systemic immunosuppression.
https://t.co/PVGGtNNTND
Meet the woman who labored for years on the technology underpinning Pfizer and Moderna's mRNA coronavirus vaccines. Many scientists thought her ideas were unworkable. But a few saw real possibilities. https://t.co/S15cWtBMxA